CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3, and wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3, or an antigen binding fragment thereof.

2. The antibody according to claim 1, wherein the antibody fragment is a Fab, Fab', F(ab')2, or scFv.

3. The antibody according to claim 1 or 2 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).

4. The antibody according to any one of the previous claims, wherein the antibody is a multi-specific antibody or antigen binding fragment thereof.

5. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the heavy chain comprises the sequence given in SEQ ID NO: 9.

6. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the light chain comprises the sequence given in SEQ ID NO: 7.

7. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO: 9 and a light chain comprising the sequence given in SEQ ID NO: 7.

8. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO: 15 and a light chain comprising the sequence given in SEQ ID NO: 11.

9. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the antibody binds to the same epitope on human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer as a neutralising antibody which binds human IL-17A and human IL-

17F and has a heavy chain comprising the sequence given in SEQ 1D NO: 9 and a light chain comprising the sequence given in SEQ ID NO: 7.

10. The antibody according to claim 9, wherein the antibody or fragment thereof is a CDR-grafted antibody.

11. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 10 in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

12. A pharmaceutical composition according to claim 11, additionally comprising other active ingredients.

13. The use of an antibody according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A OR IL-17F, or that is associated with an increased level of IL-17A or IL-17F.

14. An antibody according to any one of claims 1 to 10, a composition according to claim 11 or 12 or use according to claim 13, substantially as hereinbefore described.

CLAIMS:

1. A neutralising antibody which binds human IL-17A and human IL-17F.
2. A neutralising antibody according to claim 1 which also binds human IL-17A/F heterodimer.
3. A neutralising antibody according to claim 1 or claim 2 which has a binding affinity for IL-17F of better than 2nM.
4. A neutralising antibody according to any one of claims 1-3 which has a binding affinity for IL-17A that is at least 10 times greater than its binding affinity for IL-17F.
5. A neutralising antibody according to any one of claims 1-4 which has a binding affinity for IL-17A of better than 100pM.
6. A neutralising antibody according to any one of claims 1 to 5 which is capable of inhibiting the activity of 0.8nM human IL-17A by 50% at a concentration of less than 5nM and the activity of 4.2nM IL-17F by 50% at a concentration of less than 12nM said inhibitory activity being measured on the IL-17A or IL-17F induced release of IL-6 from Hela cells.
7. A neutralising antibody which binds human IL-17A and human IL-17F comprising a heavy chain, wherein the variable domain of the heavy chain comprises at least one of a CDR having the sequence given in SEQ ID NO:1 for CDR-H1, a CDR having the sequence given in SEQ ID NO:2 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:3 for CDR-H3.
8. A neutralising antibody according to claim 7, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.
9. A neutralising antibody which binds human IL-17A and human IL-17F, comprising a light chain, wherein the variable domain of the light chain comprises at least one of a CDR having the sequence given in SEQ ID NO:4 for CDR-L1, a CDR having the sequence given in SEQ ID NO:5 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:6 for CDR-L3.
10. A neutralising antibody according to claim 7 or claim 8, additionally comprising a light chain, wherein the variable domain of the light chain comprises at least one of a CDR

having the sequence given in SEQ ID NO:4 for CDR-L1, a CDR having the sequence given in SEQ ID NO:5 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:6 for CDR-L3.

11. A neutralising antibody according to claim 9 or claim 10 wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:6 for CDR-L3.

12. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the heavy chain comprises three CDRs and the sequence of CDRH-1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:1, the sequence of CDRH-2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:2 and the sequence of CDRH-3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:3.

13. A neutralising antibody according to claim 12, additionally comprising a light chain, wherein the variable domain of the light chain comprises three CDRs and the sequence of CDRL-1 has at least 60% identity or similarity to the sequence given in SEQ ID NO:4, the sequence of CDRL-2 has at least 60% identity or similarity to the sequence given in SEQ ID NO:5 and the sequence of CDRL-3 has at least 60% identity or similarity to the sequence given in SEQ ID NO:6.

14. An antibody according to any one of claims 7 to 11 wherein the heavy chain comprises the sequence given in SEQ ID NO:9.

15. An antibody according to any one of claims 7 to 11, wherein the light chain comprises the sequence given in SEQ ID NO:7.

16. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:9 and a light chain comprising the sequence given in SEQ ID NO:7.

17. A neutralising antibody which binds human IL-17A and human IL-17F, wherein the variable domain of the light chain comprises a sequence having at least 80% identity or similarity to the light chain variable domain of the antibody of claim 16 and wherein the variable domain of the heavy chain comprises a sequence having at least 80% identity or similarity to the heavy chain variable domain of the antibody of claim 16.

18. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.

19. A neutralising antibody which binds human IL-17A and human IL-17F, in which the heavy and light chains are at least 80% identical or similar to the corresponding heavy and light chains of the antibody of claim 18.

20. A neutralising antibody which binds human IL-17A and human IL-17F, which binds to the same epitope on human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer as the antibody of claim 16.

21. A neutralising antibody which binds human IL-17A and human IL-17F which cross-blocks the binding of the antibody of claim 16 to human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer and/or is cross-blocked from binding human IL-17A and/or human IL-17F and/or IL-17A/F heterodimer by the antibody of claim 16.

22. The antibody according to any one of claims 1-21, wherein the antibody is a whole antibody or functionally active fragment or derivative thereof.

23. The antibody according to claim 22 where the antibody fragment is a domain antibody, Fab, Fab', $F(ab')_2$, scFv or an epitope-binding fragment thereof.

24. The antibody according to claim 23, wherein the antibody or fragment thereof is a CDR-grafted antibody or a fully human antibody.

25. The antibody according to any one of claims 1-24 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).

26. An epitope on human IL-17A bound by the antibody of claim 16.

27. An epitope on human IL-17F bound by the antibody of claim 16.

28. An epitope on human IL-17A/F heterodimer bound by the antibody of claim 16.

29. An isolated DNA sequence encoding the heavy and/or light chain(s) of an antibody according to any one of claims 1 to 24.

30. A cloning or expression vector comprising one or more DNA sequences according to claim 29.

31. A vector according to claim 30, wherein the vector comprises the sequences given in SEQ ID NO:14 and SEQ ID NO:18.

32. A host cell comprising one or more cloning or expression vectors according to claim 30 or claim 31.

33. A process for the production of the antibody of any one of claims 1 to 24, comprising culturing the host cell of claim 32 and isolating the antibody.

34. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 24, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

35. A pharmaceutical composition according to claim 34, additionally comprising other active ingredients.

36. An antibody according to any one of claims 1 to 24 or a pharmaceutical composition according to claim 34 or claim 35, for use in the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F, or that is associated with an increased level of IL-17A or IL-17F.

37. The use of an antibody according to any one of claims 1 to 24 in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A or IL-17F, or that is associated with an increased level of IL-17A or IL-17F.